- Home
- AXNX vs CORT Comparison
AXNX vs CORT Comparison
Compare AXNX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXNX
- CORT
- Stock Information
- Founded
- AXNX 2012
- CORT 1998
- Country
- AXNX United States
- CORT United States
- Employees
- AXNX N/A
- CORT N/A
- Industry
- AXNX Medical/Dental Instruments
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- AXNX Health Care
- CORT Health Care
- Exchange
- AXNX Nasdaq
- CORT Nasdaq
- Market Cap
- AXNX 3.5B
- CORT 4.0B
- IPO Year
- AXNX N/A
- CORT N/A
- Fundamental
- Price
- AXNX $69.63
- CORT $45.43
- Analyst Decision
- AXNX Hold
- CORT Strong Buy
- Analyst Count
- AXNX 9
- CORT 4
- Target Price
- AXNX $70.67
- CORT $66.50
- AVG Volume (30 Days)
- AXNX 340.6K
- CORT 912.3K
- Earning Date
- AXNX 10-28-2024
- CORT 10-30-2024
- Dividend Yield
- AXNX N/A
- CORT N/A
- EPS Growth
- AXNX N/A
- CORT 39.48
- EPS
- AXNX N/A
- CORT 1.13
- Revenue
- AXNX $408,809,000.00
- CORT $569,610,000.00
- Revenue This Year
- AXNX $25.48
- CORT $39.78
- Revenue Next Year
- AXNX $19.56
- CORT $18.72
- P/E Ratio
- AXNX N/A
- CORT $40.16
- Revenue Growth
- AXNX 27.81
- CORT 33.04
- 52 Week Low
- AXNX $48.30
- CORT $20.84
- 52 Week High
- AXNX $69.91
- CORT $47.71
- Technical
- Relative Strength Index (RSI)
- AXNX 62.61
- CORT 69.51
- Support Level
- AXNX $69.10
- CORT $42.37
- Resistance Level
- AXNX $69.67
- CORT $47.71
- Average True Range (ATR)
- AXNX 0.34
- CORT 2.11
- MACD
- AXNX 0.03
- CORT 0.25
- Stochastic Oscillator
- AXNX 82.50
- CORT 74.75
About AXNX Axonics Inc.
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.